Moderna
Trade Moderna 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About MRNA
Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid. The firm's product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics.
MRNA Key Statistics
Stock Snapshot
With a market cap of 19.47B, Moderna(MRNA) trades at $51.64. The stock has a price-to-earnings ratio of -6.18.
On 2026-01-22, Moderna(MRNA) stock traded between a low of $51.50 and a high of $52.73. Shares are currently priced at $51.64, which is +0.3% above the low and -2.1% below the high.
Moderna(MRNA) shares are trading with a volume of 538.7K, against a daily average of 14.16M.
In the last year, Moderna(MRNA) shares hit a 52-week high of $52.73 and a 52-week low of $22.28.
In the last year, Moderna(MRNA) shares hit a 52-week high of $52.73 and a 52-week low of $22.28.
MRNA News
Moderna (NasdaqGS: MRNA) and Merck reported five year Phase 2b data for their personalized mRNA cancer therapy, intismeran autogene (mRNA-4157), combined with K...
U.S. stock futures rose on Thursday following Wednesday’s gains. Futures of major benchmark indices were higher. The indices settled higher on Wednesday, gaini...
Moderna (MRNA) stock surged about 16% on Wednesday and hit a new 52‑week high of $50. The strong rally came after Moderna and Merck (MRK) released five‑year fol...
Analyst ratings
70%
of 27 ratingsMore MRNA News
The vaccine maker is expanding beyond its COVID-focused offerings. Shares of Moderna (MRNA +15.84%) popped on Wednesday after the biotech leader announced posi...
Moderna (MRNA) announced an update on their ongoing clinical study. Claim 50% Off TipRanks Premium Study Overview: Moderna (MRNA) is running a long-term exten...
Moderna (MRNA) announced an update on their ongoing clinical study. Claim 50% Off TipRanks Premium Study Overview: Moderna (MRNA) is running a late-stage stud...
Moderna (MRNA) announced an update on their ongoing clinical study. Claim 50% Off TipRanks Premium Study Overview Moderna (MRNA) is running a Phase 1/2 trial...
Moderna (MRNA) announced an update on their ongoing clinical study. Claim 50% Off TipRanks Premium Study Overview: Moderna (MRNA) is running a Phase 3 study t...
Alec Stranahan, an analyst from Bank of America Securities, reiterated the Sell rating on Moderna. The associated price target was raised to $27.00. Claim 50% O...
BofA raised the firm’s price target on Moderna (MRNA) to $27 from $24 and keeps an Underperform rating on the shares. The company released five-year data for in...